Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin. Participants will administer tirzepatide or placebo along with their previous glucose lowering medications.
Your participation could last about 47 weeks and may include up to 23 visits to the study center.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
-Participants must have type 2 diabetes
-Participants must have been treated with insulin glargine (U100), once daily with or without metformin ≥3 months
-Participants must have hemoglobin A1c ≥7.0% and ≤10.5%
-Participants must be of stable weight
-Participants must have a BMI ≥23 kilograms per meter squared (kg/m2)
-Participants must not have type 1 diabetes
-Participants must not have pancreatitis
-Participants must not have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
-Participants must not have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
-Participants must not have been taking weight loss drugs, including over-the-counter medications during the last 3 months